Why I think the Aviva share price is set to storm back against the FTSE 100

FTSE 100 (INDEXFTSE: UKX) insurer Aviva plc (LON: AV) looks too cheap to ignore, says Roland Head.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Patient Aviva (LSE: AV) shareholders will be hoping that CEO Maurice Tulloch will finally make good on the firm’s promise to find “a path of stronger financial performance”.

Mr Tulloch is aware that such improvements have been promised before and said on Thursday that “this time I am determined we deliver”.

The firm’s shares have fallen by 24% over the last year, compared to a drop of just 7% for the FTSE 100. Although the dividend remains on track, many investors will be unhappy with the stock’s underperformance.

I’ve been taking a look at the latest figures from the firm. In this article, I’ll explain why I remain happy to hold the stock and believe that performance should improve.

$2bn sale in Asia?

I’ll come back to Aviva’s half-year results in a moment. Although these are interesting, the big news today was official confirmation that the company is considering a sale of its Asian division, which operates in countries including Singapore, Hong Kong and China.

In today’s results, Mr Tulloch said that the group’s Asian businesses have “excellent growth and earnings potential”. Most City analysts believe that a sale is a likely option, as this growth business could be worth more when split from the group’s mature UK operations.

Press reports ahead of today’s results suggested that the Asia businesses could be sold for more than $2bn (£1.65bn).

I don’t know how accurate this is, but this number looks reasonable to me. The group’s Asian operations have generated an operating profit of about £294m over the last 12 months. A $2bn sale price would value the Asian businesses at about 5.5 times operating profit, which seems fair to me.

Dividend increase

Today’s results showed that Aviva’s operating profit rose by 1% to £1,448m during the first half of the year. Operating earnings per share climbed 2% to 27.3p, suggesting that full-year forecasts of 60.2p per share are within reach.

Tough competition in the life insurance market meant that profits from this division fell by 8% to £1,282m. But a strong performance from the general insurance business (travel and motor cover) saw operating profit rise by 29% to £391m.

Although growth is limited, cash generation remains good. As a result, the interim dividend will rise by 3% to 9.5p per share. This suggests to me that the total dividend could reach 31p per share this year, giving the stock a prospective yield of about 8%.

My view

Today’s results are healthy enough, but the group’s lack of growth highlights the challenges facing Mr Tulloch.

I estimate that selling the Asian businesses for $2bn could be worth as much as 50p per share to Aviva. It would create a smaller, more manageable business focused on the UK and Canada. This seems logical to me — the mature markets of Western Europe and North America are different from the faster-growing markets of Asia.

Although some investors will be discouraged by Aviva’s lack of growth, I think the stock is cheap enough to offer good value regardless. After today’s results, the shares trade at a discount to their book value of 432p and with a forecast price/earnings ratio of just 6.3.

The dividend also looks safe to me, with good cover from earnings and cash flow. In my view, this means that this 8% yield could be a strong buy for income investors.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Roland Head owns shares of Aviva. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »